Wed, Jul 23, 2014, 6:31 AM EDT - U.S. Markets open in 2 hrs 59 mins

Recent

% | $
Click the to save as a favorite.

Affymax, Inc. (AFFY) Message Board

  • maxdad01 maxdad01 Jun 4, 2013 7:13 PM Flag

    100's (HUNDREDS) of Rx's on the market with FATALITY WARNINGS AND MANY

    with far worse mortality stats than Omontys. Just do a little google research or even easier, watch the evening news and see how many provide the mandatory caveat "and in some cases causes death"...

    3 out of 25,000 (2 have already been ruled unrelated), while tragic, is NOT statistically significant in this industry. If every drug that had that mortality rate (or worse) was pulled from the market, there wouldn't be a whole lot left...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Maxdad is up to his old GS "steal from retail" Heinz trade tricks again. I will try to put his assurances that all is well into proper perspective. [ I am prepared for him to go ballistic again too.]

      An AFFY investor ought not to just look at .02% O deaths and think everything is OK. A 02% O kill rate is too high: Dr. Daniel W. Coyne, a kidney specialist at Washington University in St. Louis, in a NY Times article recognized that “two in 10,000 deaths on first exposure is unacceptable, compared to nothing like this” with Epogen/Aranesp. An AFFY investor also might ask what did the Fresenius letter fail to disclose? We just don't know. Nonetheless we can infer there must be other serious patient safety from what we do know. For example, RW Baird analyst Christopher Raymond's research, made after O was recalled, concluded "[L]ooking at FDA’s adverse event database for Epogen, Omontys appears to confer a 100-fold higher incidence of hypersensitivity and an 8.5-fold higher incidence of drug-related death (and that’s new). This analysis isn’t perfect, but we think the magnitude is such that there’s a clear signal here.” Also, at the time O was voluntarily recalled, Howard Sklamberg, J.D., director of the Office of Compliance at the FDA's Center for Drug Evaluation and Research, warned: "Due to the severity of the public health risk, [the FDA] want[s] to be certain that health care providers stop using Omontys."

    • I agree with your statement but somethings up and its not looking good for the company. I am neither long or short thought about buying this morning but didnt pull the trigger. After the FDA allows the drug to be on the market the company voluntarily pulls it. Then the Naz goes about delisting and the company doesnt even put up a fight, The wizard of oz is definitly pullinmg the strings behind the curtains. AFFY didnt have to pull the drug but they did, I bet the drug works great and you will see some big pharma company come in and buy affy for pennies on the dollar, I could be wrong but the recent situation tells me somethings up and its not going to benefit shareholders. I hope Im wrong for longs sake never really like shorting seems like anti-investing to me

    • i do not think there would be any drugs left on the market if that were the case.
      This is really iffy now though.
      Still, no one knows what is going to happen.
      Who knows maybe Takeda wants AFFY to just go under.
      Maybe Takeda will try and sell their license agreement to someone else.
      No idea, lets hope for the buyout though

    • max: I agree, as I have mentioned before, Off-Label uses of FDA approved drugs should be far more concerning because they dont need FDA approval for its off-label use and therefore limited to no black labeling. I just wrote to Jagan, it just sounds to coincidental that the CEO went to Amgen, a company whose market share could be greatly effected by Affy's success. Amgen would double corner this particular market need, while getting a 2017 patent expiration, and they already have a relationship with Takeda, Frensius, and manufacturers and distributors. If so, how does Goldman Sachs negotiate this? Thanks

      • 1 Reply to e.kovak
      • kovak: Due to O's market AMGN negotiated contracts at substantially lower prices (see their Q's numbers) just to thwart O's penetration.

        it is hurting them, they can't lower their manufacturing costs.

        What O is a Synthetic peptide, easy to manufacture and at a much lower cost.

        AMGN might be thrilled to get into this space, will TAKEDA give in?

        GLTA LONGS!

        Sentiment: Strong Buy

 
AFFY
0.1015+0.0005(+0.50%)Jul 22 3:19 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.